🔎 Trials Near Me

Beranda › Neoplasma Mieloproliferatif › South Carolina

Uji klinis Neoplasma Mieloproliferatif di South Carolina

5 studi untuk Neoplasma Mieloproliferatif mencari peserta di lokasi di South Carolina.

Kota di South Carolina

Teks studi resmi (Bahasa Inggris)

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Prisma Health Cancer Institute - Spartanburg, Boiling Springs
  • Medical University of South Carolina, Charleston
  • Prisma Health Cancer Institute - Easley, Easley
  • dan 5 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT05564390

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • Prisma Health Cancer Institute - Spartanburg, Boiling Springs
  • Medical University of South Carolina, Charleston
  • Prisma Health Cancer Institute - Easley, Easley
  • dan 5 lainnya
Menerima pesertaFase 2
Usia 18 hingga 59 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT05554406

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

  • MUSC Health University Medical Center, Charleston
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT04996875

Project: Every Child for Younger Patients With Cancer

  • Medical University of South Carolina, Charleston
  • Prisma Health Richland Hospital, Columbia
  • BI-LO Charities Children's Cancer Center, Greenville
  • dan 2 lainnya
Menerima pesertaStudi observasional
Hingga usia 25 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT02402244

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Greenville
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.